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Foxd3Interactions between cells from the ectoderm and mesoderm inﬂuence development of the endodermally-
derived pancreas.Whilemuch is known about howmesoderm regulates pancreatic development, relatively little
is understood about how andwhen the ectodermally-derived neural crest regulates pancreatic development and
speciﬁcally, beta cell maturation. A previous study demonstrated that signals from the neural crest regulate beta
cell proliferation and ultimately, beta cell mass. Here, we expand on that work to describe timing of neural crest
arrival at the developing pancreatic bud and extend our knowledge of the non-cell autonomous role for neural
crest derivatives in the process of beta cell maturation. We demonstrated that murine neural crest entered the
pancreatic mesenchyme between the 26 and 27 somite stages (approximately 10.0 dpc) and became
intermingled with pancreatic progenitors as the epithelium branched into the surrounding mesenchyme.
Using a neural crest-speciﬁc deletion of the Forkhead transcription factor Foxd3, we ablated neural crest cells that
migrate to the pancreatic primordium. Consistent with previous data, in the absence of Foxd3, and therefore the
absence of neural crest cells, proliferation of insulin-expressing cells and insulin-positive area are increased.
Analysis of endocrine cell gene expression in the absence of neural crest demonstrated that, although the number
of insulin-expressing cells was increased, beta cell maturation was signiﬁcantly impaired. Decreased MafA and
Pdx1 expression illustrated the defect in beta cellmaturation;we discovered thatwithout neural crest, therewas
a reduction in the percentage of insulin-positive cells that co-expressed Glut2 and Pdx1 compared to controls. In
addition, transmission electron microscopy analyses revealed decreased numbers of characteristic insulin
granules and thepresenceof abnormal granules in insulin-expressing cells frommutant embryos. Together, these
data demonstrate that the neural crest is a critical regulator of beta cell development on two levels: by negatively
regulating beta cell proliferation and by promoting beta cell maturation.ve, Nashville, TN 37232-0494,
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A fundamental question in the ﬁeld of developmental biology is
how cells from one germ layer regulate normal development of a
separate germ layer. Organdevelopment is synchronously regulated toassure proper postnatal function, and coordination of innervationwith
morphogenesis is critical to this process. This issue is of particular
interest to investigators studying pancreatic development; it is well
known that endodermdevelopment is dependent upon signaling from
surrounding mesoderm tissues. Factors secreted by the mesoderm-
derived notochord are largely responsible for development of the
dorsal pancreas bud; in the absence of the notochord, expression of
pancreas and endocrine cells markers is eliminated (Kim et al., 1997).
In addition to the notochord, the developing vasculature produces
inductive cues to inﬂuence early endoderm differentiation (Jung et al.,
1999; Lammert et al., 2001). Subsequent to this induction, signals from
mesodermally-derived pancreatic mesenchyme regulate proliferation
of pancreatic progenitors to promote pancreatic outgrowth (Golosow
and Grobstein, 1962; Wessells and Cohen, 1967). Speciﬁcally, FGF10
signaling from pancreatic mesenchyme maintains Ptf1a expression in
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and branching morphogenesis of the developing pancreas (Bhushan
et al., 2001; Jacquemin et al., 2006).
In addition tomesodermally-derived tissues, a role for ectodermally-
derived tissues in pancreas developmentwas recently described. While
ectodermally-derived neural signals had been implicated in growth
and/or function of adult endocrine pancreas (Edvell and Lindstrom,
1998; Imai et al., 2008; Razavi et al., 2006), a recent study demonstrated
for the ﬁrst time that the ectodermally-derived neural crest regulates
embryonic development of the pancreas (Nekrep et al., 2008).However,
the relationship between neural crest populating the pancreas and the
developmental switch between immature insulin-expressing cells to
mature beta cells remained unclear. Neural crest is a multipotent
embryonic cell lineage that migrates ventrally from the dorsal neural
tube and, among other functions, generates enteric nervous system
derivatives that innervate endodermally-derived organs of the gut (Le
Douarin, 1999). Molecular control of speciﬁcation, maintenance,
migration and function of the neural crest is at least partially controlled
by the transcription factors Sox10 and Foxd3 (Labosky and Kaestner,
1998; Nelms and Labosky, 2010; Sauka-Spengler and Bronner-Fraser,
2008; Southard-Smith et al., 1998). Phox2b is a downstream target of
Sox10, and both Phox2b and Sox10 are required for neural and glial
differentiation in the gut (Herbarth et al., 1998; Pattyn et al., 1999;
Southard-Smith et al., 1998). Phox2b−/− embryos lack neural crest cells
within the pancreas, resulting in a profound increase in proliferation of
insulin-expressing cells (Nekrep et al., 2008). To date, this model of
neural crest regulation of beta cell proliferationhas not beenvalidated in
an independent neural crest-deﬁcient system, and the timing of neural
crest arrival into thepancreatic primordiumhadnot beendescribed. The
transcription factor Foxd3, one of the earliest markers of neural crest
(Labosky and Kaestner, 1998), is required for maintenance of neural
crest progenitors. In the absence of neural crest expression of Foxd3,
there is a catastrophic loss of this lineage including the entire enteric
nervous system (Teng et al., 2008). Using neural crest-speciﬁc lineage
labeling,wedetermined the timingandpatterningof neural crest arrival
at thedevelopingpancreas. In addition,witha geneticmanipulation that
disrupts neural crest, we demonstrate that pancreatic beta cell
development and maturation depends on interactions with neural
crest derivatives.
Materials and methods
Mouse lines
Tg(Wnt1-Cre)11Rth (referred to as Wnt1-Cre), two independent
Foxd3null alleles, Foxd3tm1.Lby and Foxd3tm2.Lby (Foxd3−), and Foxd3tm3.Lby
(Foxd3ﬂ) mice were interbred to generate Foxd3ﬂ/+ (control) and
Foxd3ﬂ/-; Wnt1-Cre (mutant) embryos. These mouse lines and
genotyping were previously described (Danielian et al., 1998;
Hanna et al., 2002; Teng et al., 2008). For lineage analyses, a reporter
allele,Gt(ROSA)26Sortm1(EYFP)Cos (R26RYFP, (Srinivas et al., 2001)),was
also used. Mice were maintained on an outbred genetic background
consisting of CD-1, 129S6 and C57BL/6J. All mouse lines were
maintained under protocols approved by the Vanderbilt University
Institutional Animal Care and Use Committee (IACUC). To generate
embryos for dissections and further analysis, mice of the appropriate
genotypes were mated, dams checked daily for the presence of a
vaginal plug, and noon on the day of the plug considered 0.5 days
post coitum (dpc). To measure BrdU incorporation, pregnant dams
were injected with 0.5 mg BrdU/kg body weight 1 hour before
sacriﬁce.
Histology and immunohistochemistry
At 11.5 dpc or younger, embryos were dissected from the placenta
and surrounding maternal tissues and ﬁxed in 4% paraformaldehyde(PFA) in PBS for 4 hours. For embryos aged 13.5 dpc or older, the
pancreas, duodenum, stomach, and spleen were dissected from the
embryo in cold PBS and ﬁxed in 4% PFA in PBS for 4 hours. Yolk sacs or
embryonic tissues were removed for DNA extraction and PCR
genotyping. Tissues were processed, embedded, and sectioned
following standard procedures (Presnell and Shreibman, 1997). For
whole mount immunohistochemistry, 9.5 to 10.25 dpc embryos were
ﬁxed and then permeabilized in 0.5 % Triton X-100 at room
temperature for 30 minutes. Non-speciﬁc antigen recognition was
minimized by blocking in 1% BSA, 10% normal donkey serum and 0.1%
Triton X-100 in PBS. Embryos were then incubated with primary
antibodies, washed, and subsequently incubated with secondary
antibodies; each step was performed overnight at 4 °C. Finally,
samples were washed overnight in PBS with 0.1% Triton X-100. For
9.5–10.25 dpc embryos, the hindlimb and surface ectoderm were
removed and the gut tube was separated from the neural tube to
facilitate imaging. The following primary antibodies were used:
chicken anti-GFP (1:500, Abcam), mouse anti-β-III Tubulin (1:500,
Covance,TUJ1), rabbit anti-PGP9.5 (1:1000, AbD Serotec) rabbit anti-
Fabp7 (1:1000, a kind gift from Dr. Thomas Muller, (Kurtz et al., 1994;
Schnutgen et al., 1996)), guinea pig anti-Pdx1 (1:2500) and goat anti-
Pdx1 (1:10000, both Pdx1 antibodies were kind gift from Dr.
Christopher Wright, (Boyer et al., 2006; Hingorani et al., 2003)),
guinea pig anti-insulin (1:500,Millipore), rabbit anti-glucagon (1:500,
Millipore), rabbit anti-pancreatic polypeptide (1:100, Millipore), rat
anti-somatostatin (1:100, Millipore), rabbit anti-ghrelin (1:100,
Phoenix Pharmaceuticals), rabbit anti-Glut2 (1:1000, Millipore), rat
anti-BrdU (1:250, Accurate Biochemical), mouse anti-Neurog3
(1:1000, Developmental Studies Hybridoma Bank), rabbit anti-Foxd3
(1:1000, (Tompers et al., 2005)). The secondary antibodies usedwere:
biotin donkey anti-chicken (1:500), biotin donkey anti-mouse
(1:500), Cy2 donkey anti-mouse (1:500), Cy2 donkey anti-guinea
pig (1:500), Cy2 donkey anti-rabbit (1:500), Cy3 donkey anti-mouse
(1:500), Cy3 donkey anti-guinea pig (1:500), Cy3 donkey anti-rabbit
(1:500), Cy3 donkey anti-rat (1:500), Cy3 donkey anti-goat (1:800),
Cy5 donkey anti-rabbit (1:500), Cy5 donkey anti-mouse (1:500), and
Cy5 donkey anti-guinea pig (1:500). All secondary antibodies were
purchased from Jackson ImmunoResearch. To detect YFP and Neurog3
protein, tyramide signal ampliﬁcation was used (Invitrogen). BrdU
was detected as previously described (Plank et al., submitted for
publication; Teta et al., 2007). Tissue sections were imaged using
either a Zeiss Axioskop2 pluswith a Q-Imaging Retiga 2000R Fast 1394
camera or an Olympus FV1000 Confocal Laser Scanning Microscope.
Transmission electron microscope (TEM) analyses were completed
with the assistance of the Vanderbilt Cell Imaging and Shared Resource
using standard procedures (Tweedie et al., 2006).
Quantiﬁcation and statistical analysis
To quantify pancreatic alpha, beta, delta, epsilon, and PP cell area,
the glucagon-, insulin-, somatostatin-, ghrelin-, or PP-positive area
was determined using ImageJ (NIH) and divided by the total
pancreatic area from 5-7 evenly spaced sections throughout the
pancreas. Approximately 10% of the total pancreatic area was
quantiﬁed for each cell type. Similarly, Neurog3-positive cells were
quantiﬁed: the number of Neurog3-positive cells per section was
divided by the pancreatic area. The percent of Glut2- and/or Pdx1-
positive insulin-expressing cells was calculated by counting the
number of insulin-expressing cells co-expressing Glut2 and/or Pdx1
divided by the total number of insulin-expressing cells. Two
endocrine cell clusters from 5 evenly spaced sections throughout
the pancreas were analyzed (10 clusters total at each age). At least
250 insulin-positive cells from each animal were counted. The percent
of endocrine cell clusters in contact with neurons was calculated by
determining the number of endocrine cell clusters (in this assay, a
cluster was deﬁned as having more than 5 cells) in contact with
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section. At least 4 evenly spaced sections throughout the pancreas
were analyzed per embryo ormouse, accounting for approximately 5%
to 8% of the total pancreatic area. Statistical signiﬁcance for each assay
was determined using a two-tailed Student's t-test.
RNA isolation and real time PCR
The pancreatic primordium was dissected and stored in RNA Later
(Ambion). RNA was isolated using QIAshredder columns and the
RNeasy Mini Kit (Qiagen) and contaminating genomic DNA removed
with Turbo DNase (Ambion). cDNA was generated using the
Superscript First Strand Synthesis (Invitrogen) and 2 ng of cDNA
was ampliﬁed using Power SYBR Green PCR Master Mix (Applied
Biosystems). All samples were run in duplicate and 4–6 biological
replicates were used in each case. The relative amount of mRNA was
determined by comparison toHypoxanthine Phosphoribosyl Transferase
(Hprt) and a two-tailed Student's t-test was used to determine
statistical signiﬁcance. Primer sequences are in Table 1.
Results and discussion
Neural crest arrival at the pancreatic primordium occurs between the 26
and 27 somite stages
Signals from the neural crest regulate proliferation of insulin-
expressing cells that in turn inﬂuence initial beta cell mass (Nekrep
et al., 2008); however, the timing of interactions between neural crest
and the pancreatic primordium has not been carefully deﬁned. By
9.0 days post coitum (dpc, 13–15 somites) the endoderm-derived gut
epithelium forms two outpocketings that will become the dorsal and
ventral pancreatic buds. Mesoderm-derived pancreatic mesenchyme
surrounds both buds, and interactions between these tissues are
required for subsequent branchingmorphogenesis (Gittes et al., 1996;
Golosow and Grobstein, 1962). To determine when migratory neural
crest ﬁrst makes physical contact with the pancreatic primordium, we
analyzed the neural crest lineage in Wnt1-Cre; R26RYFP/+ (control)
embryos from 9.5 dpc to 10.25 dpc. At the 26 somite stage (10.0 dpc),
YFP-positive neural crest cells were detected in the anterior foregut
(Fig. 1A) but were not in the vicinity of the pancreatic primordium
(Fig. 1D). The pancreatic epithelium was identiﬁed by Pdx1 expres-
sion. However, by the 27 somite stage and afterwards (Fig. 1B–C), YFP-
positive neural crest cells were present within the pancreatic
mesenchyme adjacent to the epithelium. This demonstrated that
neural crest arrival at the pancreatic primordium begins between
the 26 and 27 somite stages (approximately 10.0 dpc). Additionally,
because a new pair of somites is formed approximately every 2 hours
in the mouse embryo (Tam, 1981), these data provide, for the ﬁrst
time, a precise characterization of the timing of neural crest migration
to the pancreatic primordium. These data suggest that neural crest is
proximal to the pancreatic epithelium well in advance of signiﬁcantTable 1
Primer sequences used for qPCR.
Gene name Forward primer sequence
(5’→3’)
Reverse primer sequence
(5’→3’)
Gcg AGGAATTCATTGCGTGGCTG CAATGGCGACTTCTTCTGGG
Ins1 CAGCAAGCAGGTCATTGTTT GGGACCACAAAGATGCTGTT
Mafa TCGACCTGATGAAGTTCGAG CAGAAGCTGGGCGAAGAG
Mafb CCCACACATTGGCAACTAAC AACGGAAGGGACTTGAACAC
Neurog3 ATCCATCACTTTTTCCAGGGTG TCATCTATGGGCCAAGAGCTG
Nkx2.2 GCAGCGACAACCCCTACA ATTTGGAGCTCGAGTCTTGG
Pdx1 CTGAGGGACAAAGATGCAGA TTCTAATTCAGGGCGTTGTGbranching and the secondary transition, a key developmental stage
initiating around 13.5 dpc that marks a wave of insulin-positive cell
differentiation. In addition, this contradicts previous studies conclud-
ing that only mesodermally- and endodermally-derived tissues were
present in dorsal pancreatic buds at 11.5 dpc (Horb and Slack, 2000;
Percival and Slack, 1999).We also observed that neural crest enters the
mesenchyme surrounding the dorsal pancreas prior to the ventral
pancreas; YFP-positive neural crest cells are present in the mesen-
chyme surrounding the dorsal pancreas by the 27 somite stage
(Fig. 1E–F) while YFP-positive cells are not detected adjacent to the
ventral pancreas until the 28 somite stage (Fig. 1G–H). This timing
conﬁrms that neural crest arrival at the pancreatic buds parallels the
timing of pancreas development as the dorsal bud undergoes
branching morphogenesis and expansion slightly earlier than the
ventral bud (Jorgensen et al., 2007).
Foxd3 is required for neural crest arrival at the developing pancreas
Loss of Foxd3 in the neural crest results in a loss ofmost neural crest
derivatives, however, some regions of the embryo, such as the outﬂow
tract, are only mildly perturbed (Teng et al., 2008). To determine if
Foxd3 function in the neural crest is required for the neural crest that
migrates to the developing pancreas, we analyzed the neural crest
lineage in control and mutant embryos with a Cre-activatable lineage
label,R26RYFP/+. In contrast to controls (Fig. 2A–B),mutant neural crest
cells, identiﬁed with YFP expression, were not found near the
pancreatic epithelium, identiﬁed by Pdx1 and Glucagon expression,
at 10.5 or 11.5 dpc (Fig. 2E–F). These data conﬁrm a cell autonomous
requirement for Foxd3 within neural crest fated to enter the pancreas.
To further characterize neural crest in control embryos and
determine if neural crest cells were present in the pancreata of
mutant embryos at later developmental time points, we analyzed the
neural crest lineage at 15.5 and 17.5 dpc. As pancreatic development
progresses, the branches of pancreatic epithelium, identiﬁed by Pdx1
expression, invade the surrounding mesenchyme, and we observed
neural crest cells interspersed throughout the developing pancreas
(Fig. 2C–D). However, neural crest cells were never present near the
pancreas in mutant embryos (Fig. 2G–H) supporting our earlier
observations that Foxd3 expression in the neural crest is required for
maintenance of neural crest (Teng et al., 2008), including neural crest
derivatives in the pancreas.
Neurons and glia are absent in mutant pancreata
Normally, neural crest cells differentiate to form neurons and glia
of the sensory, sympathetic, and enteric nervous systems (Adams and
Bronner-Fraser, 2009) and in a previous report using mouse embryos
homozygous for a null mutation in Phox2b (Phox2b−/−) lacking much
of the neural crest, neurons and glia are absent from the pancreas
(Nekrep et al., 2008). To further characterize this ﬁnding using a
neural crest-speciﬁc mutation, we analyzed the timing of neural and
glial differentiation in pancreata from control embryos at various
developmental stages. Very few TUJ1-positive neurons and no FABP7-
positive glia were present at 13.5 dpc (data not shown). However, by
15.5 and 17.5 dpc, both neurons and glia were intermingled with
pancreatic epithelial cells, identiﬁed by Pdx1 expression (Fig. 3A–B),
suggesting that neural and glial differentiation in the pancreas began
between 13.5 and 15.5 dpc and neural crest derivatives are in position
to affect beta cell development by the beginning of the secondary
transition. In addition, by 17.5 dpc, neurons and glia are closely
associated with cells expressing high levels of Pdx1, indicative of
endocrine cells. Consistent with our earlier observations (Figs. 1 and 2),
Foxd3 mutant embryos completely lacked neurons and glia in the
pancreas (Fig. 3C–D) supporting our conclusion that pancreatic neurons
and glia are derived from the neural crest.
Fig. 1. Neural crest cells enter the pancreatic primordium between the 26 and 27 somite stages. (A–C). Whole mount immunoﬂuorescence for Pdx1 marking the pancreatic
epithelium (red), and YFP marking neural crest cells (green), illustrates the path and timing of neural crest migration. In these samples neural crest was lineage labeled with Wnt1-
Cre driven recombination of R26RYFP in control embryos (Wnt1-Cre; R26RYFP/+). Neural crest cells have not reached the pancreatic primordium by the 26 (A) somite stage, by the 27
somite stage (B)migrating neural crest cells had just reached the pancreatic epithelium, and at the 28 somite stage (C), the leading edge of the neural crestmigratory streamwas past
the pancreatic primordium. (D–F) Higher magniﬁcation of the dorsal and ventral pancreatic buds illustrate that the YFP-positive neural crest cells have not reached the dorsal bud at
the 26 somite stage (D) but have arrived at the dorsal bud at the 27 somite stage (E) and the ventral bud at the 28 somite stage (F). (G–H) Higher magniﬁcation images of the ventral
bud demonstrate no YFP-positive neural crest cells present near the ventral bud at the 27 somite stage (G) but neural crest are at the ventral bud at the 28 somite stage (H). The
cartoon illustrates the orientation of the embryos with the boxed region corresponding to the area shown in A–C. VP, ventral pancreas; DP, dorsal pancreas; *, sympathetic ganglia.
N=2–3 embryos per somite stage.
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insulin-positive area
Analysis of the Phox2b−/− embryos lacking neural crest demon-
strated that signals from the neural crest regulate insulin-expressing
cell proliferation and the total number of insulin-expressing cells
(Nekrep et al., 2008). In Phox2b−/− embryos, neural crest cells migrate
to the endoderm of the foregut but then undergo apoptosis prior to
differentiating into enteric neurons (Pattyn et al., 1999). Because the
neural crest is more signiﬁcantly ablated in Foxd3 neural crest-
conditional null embryos (no neural crest cells migrate into the
foregut in mutants, (Teng et al., 2008)), it leaves open the possibility
that beta cell development may be more severely altered in this
genetic model. To determine if the insulin-expressing cell area is
greater in Foxd3 neural crest mutant embryos, we assayed insulin-
and glucagon-positive area in mutant and control pancreata at 17.5
dpc. Similar to the previous study, the area occupied by insulin-
expressing cells in the pancreas was increased approximately 1.5 fold
(Fig. 4A) while glucagon-positive area was unchanged (Fig. 4B)
in mutants compared to controls. In addition, we analyzed PP-,
somatostatin-, and ghrelin-positive area and found that the area of
these endocrine cell lineages was similar betweenmutant and control
embryos (Fig. 4C). To determine if Nkx2.2 expression, a transcription
factor required for initial beta cell differentiation and, to a lesser
extent, alpha and PP cell differentiation was altered in our system(Sussel et al., 1998), we used real time PCR (qPCR) to analyze Nkx2.2
mRNA expression. At both 13.5 and 15.5 dpc, Nkx2.2was signiﬁcantly
increased (Fig. 4D), consistent with previous ﬁndings (Nekrep et al.,
2008). To resolve whether the increase in insulin-positive area was
due to changes in cell proliferation, we assayed BrdU incorporation in
mutant and control pancreata. In both 15.5 and 17.5 dpc embryos,
BrdU incorporation was increased (85% at 15.5 dpc and 29% at 17.5
dpc) in insulin-expressing cells from embryos lacking Foxd3 in the
neural crest (Fig. 4E). These results suggested that neural crest-
derived cells negatively regulate proliferation in insulin-expressing
cells. In contrast, BrdU incorporation in glucagon-expressing cells of
control and mutant embryos was unchanged at both times (Fig. 4F).
These data agree with the previous report that signals from the neural
crest regulate insulin-expressing, but not glucagon-expressing, cell
area and proliferation (Nekrep et al., 2008).
Neural crest cells do not regulate beta cell neogenesis
While proliferation changes profoundly inﬂuence the ﬁnal number
of beta cells, endocrine cell neogenesis also plays a signiﬁcant role. To
analyze beta cell neogenesis, we quantiﬁed Neurog3 mRNA expres-
sion, an indicator of endocrine cell neogenesis (Gu et al., 2002;
Schwitzgebel et al., 2000). qPCR analyses demonstrated increased
Neurog3 expression in pancreata from mutant embryos at both 13.5
and 15.5 dpc (Fig. 4G), when Neurog3 is playing a profound role in the
Fig. 2. The neural crest does not populate the pancreas in the absence of Foxd3.
(A–B) Immunoﬂuorescence on sections of embryonic tissue demonstrated that YFP-
positive neural crest cells (green) are adjacent to the Pdx1-positive pancreatic epithelium
(red) at 10.5 (A) and 11.5 dpc (B) in control embryos (Wnt1-Cre; Foxd3ﬂox/+; R26RYFP/+).
(C–D) As pancreatic branching ensues, YFP-positive neural crest cells (green) become
intermingled with pancreatic epithelial cells (red) and are closely associated with cells
expressinghigher levels of Pdx1 at15.5 (C) and17.5dpc (D). (E–H)YFP-positive cellswere
not detected in the pancreatic primordium of mutant embryos (Wnt1-Cre; Foxd3ﬂox/;
R26RYFP/+) at any developmental time point. Arrows illustrate YFP-expressing cells. Scale
bars, 100μm. N=3–4 embryos in each group.
Fig. 3. Neurons and glia are absent in pancreata from embryos with a neural crest
speciﬁc deletion of Foxd3. (A–B) Immunoﬂuorescent analyses of sections of embryonic
pancreata demonstrated that TUJ1-positive neurons (red) and FABP7-expressing glia
(blue) were present in control pancreata at 15.5 (A) and 17.5 (B) dpc. TUJ1- and FABP7-
positive cells were not detected at any stages in mutant pancreata (C–D). The pancreas
was indicated by Pdx1-positive cells (green). Arrows, TUJ1-positive cells; arrowheads,
FABP7-positive cells. N=3–4 embryos in each group.
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with 2 possibilities: (1) an increase in Neurog3 mRNA expression per
individual cell or (2) an increase in the number of cells expressing
Neurog3, suggesting increased endocrine cell neogenesis. To distin-
guish between these two explanations, we used immunohistochem-
istry and quantiﬁed the total number of Neurog3-positive cells per
pancreatic area and discovered that the number of cells expressing
Neurog3 was similar between mutants and controls (Fig. 4H)
suggesting that neural crest cells are not required for endocrine cell
neogenesis, but that regulation of Neurog3 levels on a per cell basis
was disrupted. During embryogenesis, Neurog3-positive precursors
are unipotent (Desgraz and Herrera, 2009); therefore, it is possible
that individual endocrine progenitors expressing high levels of
Neurog3may be mis-speciﬁed to a beta cell fate resulting in increased
insulin-positive area. Because we did not detect changes in the
proportion of other pancreatic endocrine cells in mutant embryos
(Fig. 4B–C), it is unlikely that endocrine progenitors are reallocated toa beta cell fate. However, the possibility remains open that Neurog3
may regulate other aspects of beta cell development such as self-
renewal and maturation.
Neural crest cells regulate beta cell maturation
Although increased insulin-expressing cell area is signiﬁcant, it is
more physiologically important that the insulin-expressing cells are
capable of responding to glucose stimulation. Unfortunately, embryos
with a neural crest-speciﬁc deletion of Foxd3 or a homozygous null
mutation in Phox2b result in perinatal lethality, so beta cell function
cannot be tested in postnatal animals. As an alternative, we ﬁrst
examined expression of deﬁnitive markers of mature beta cells. The
transcription factor MafA is a key regulator of glucose stimulated
insulin secretion and is expressed upon maturation (Zhang et al.,
2005). Similarly, Pdx1 is strongly expressed in mature beta cells
(Ohlsson et al., 1993). Alternatively, MafB is expressed in immature
insulin-expressing cells and immature andmature glucagon-expressing
cells while glucagon (Gcg) is expressed in all alpha cells (Artner et al.,
2006; Matsuoka et al., 2003). Therefore, to determine if signals from
neural crest-derivatives are required for beta cell maturation, we
analyzed mRNA expression of MafA and Pdx1 in addition to MafB, Ins1,
and Gcg at 17.5 dpc. Expression of MafB and Gcg were unchanged in
mutant embryos while expression of Ins1 appeared increased inmutant
embryos, although this trend was not statistically signiﬁcant. Impor-
tantly, expression of both MafA and Pdx1 mRNA was signiﬁcantly
decreased, suggesting that signals from neural crest derivatives
positively regulate beta cell maturation (Fig. 5A). To examine beta cell
maturation on a more cell biological level, we analyzed protein
expression of Pdx1 and Glut2, the glucose transporter utilized by beta
Fig. 4. Neural crest-derived cells regulate insulin-expressing cell expansion. (A) The insulin (Ins)-positive area frommutants and controls was calculated and indicated that mutants
have a greater Ins-positive area than controls at 17.5 dpc. (B) The glucagon (Gcg)-positive area was similar betweenmutants and controls at 17.5 dpc. (C) The pancreatic polypeptide
(Ppy), somatostatin (Sst), and ghrelin (Ghrl)-positive areas were slightly increased but not to a statistically signiﬁcant level in mutants compared to controls at 17.5 dpc. (D) qPCR
analyses indicated that Nkx2.2mRNA expression was increased in mutants compared to controls at 13.5 and 15.5 dpc. (E) BrdU incorporation in insulin-positive cells was greater in
mutants than controls at 15.5 and 17.5 dpc. (F) BrdU incorporation in Gcg-positive cells was unchanged in mutants and controls at 15.5 and 17.5 dpc. (G) qPCR analyses indicated
Neurog3mRNA expression was increased in mutants compared to controls at 13.5 and 15.5 dpc. (H) The total number of Neurog3-positive cells per pancreatic area was unchanged
between mutants and controls at 13.5 and 15.5 dpc. Purple lines and bars represent control embryos; red bars, represent mutant embryos. Error bars indicate SEM. *pb0.05,
**pb0.01. N=3–5 embryos per group.
326 J.L. Plank et al. / Developmental Biology 349 (2011) 321–330cells that is critical for glucose stimulated insulin secretion (Guillam
et al., 1997). There was a signiﬁcant decrease (approximately 6%) in the
percentage of insulin-positive cells co-expressing Glut2 and Pdx1
(Figs. 5B-D). Additionally, there was an increase (approximately 15%)
in the percentage of insulin-positive cells that do not express Pdx1 or
Glut2, further suggesting a decrease in beta cell maturation (Fig. 5B–D).
We extended this analysis of Pdx1 and Glut2 expression to 18.5 dpc and
found similar results. Again, we observed an increase the percentage of
cells expressing insulin but not Pdx1 or Glut2 (Fig. 5E–G). Our data
demonstrate that although the majority of insulin-expressing cells co-
express Pdx1 and Glut2, there is a signiﬁcant fraction of insulin-expressing cells that do not express Pdx1 or Glut2. The presence of this
small but signiﬁcant population of cells supports the conclusion that
signals from neural crest derivatives are critical for beta cell maturation.
To analyze beta cell maturation at higher resolution, we used
transmission electron microscopy (TEM). Mature insulin containing
granules can be identiﬁed by the presence of electron dense cargo
surrounded by an electron-free halo (Fig. 5H–I, black arrows) while
immature insulin containing granules can be identiﬁed by the
presence of less dense cargo surrounded by the characteristic halo
(Fig. 5H-I, white arrows). These criteria were applied for the
identiﬁcation of insulin-expressing cells. Our TEM analyses revealed
Fig. 5. Beta cell maturation is impaired in the absence of neural crest. (A)MafA and Pdx1mRNA was decreased in mutants (red bars) compared to controls (purple line) whileMafB,
Ins, and Gcg mRNA were similar between mutants and controls at 17.5 dpc. N=5 pancreata in each group. (B–G) Immunoﬂuorescent analyses of Pdx1 (blue) and Glut2 (red)
expression in insulin-positive cells (green) indicated that a greater proportion of insulin-positive cells from mutant embryos (C, F) do not co-express Glut2 or Pdx1 compared to
control littermates (B, E) at 17.5 (B–C) and 18.5 dpc (E–F). Quantiﬁcation of immunoﬂuorescent analyses at 17.5 dpc (D) indicated that the proportion of Ins-positive cells that do not
express Glut2 or Pdx1 (blue portion of the graph) was increased while the proportion of insulin-positive cells that co-expressed both Pdx1 and Glut2 (red) are decreased in mutant
embryos. Quantiﬁcation of immunoﬂuorescent analyses at 18.5 (G) indicated that the proportion of insulin-positive cells that do not co-express Glut2 or Pdx1 (blue) was increased
in mutant embryos. Arrows indicate insulin-positive cells that do not express Pdx1 or Glut2. N=3-4 embryos per group. *pb0.05, **pb0.01, ***pb0.001. Note the vertical y-axis
extends from 80% to 100%. (H–I) Transmission electron microscopy revealed there were fewer insulin granules in pancreata from mutant embryos (I) compared to controls (H) at
17.5 dpc. Additionally, abnormal granules in insulin-expressing cells were also present in mutant samples but not in controls. Black arrows indicate examples of mature insulin
granules, white arrows indicate examples of immature insulin granules, and white arrowheads indicate examples of abnormal granules. n, nucleus; dashed line, nuclear membrane;
solid line, cell membrane. Scale bars represent 500 nm. Error bars represent SEM.
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embryos (Fig. 5I). First, the number of granules in all cells analyzed
from mutant embryos was decreased compared to controls (Fig. 5H).Second, although some granules from mutant embryos had the
morphology characteristic of insulin granules, a signiﬁcant proportion
of the granules in 3 out of 6 cells from mutant embryos were
328 J.L. Plank et al. / Developmental Biology 349 (2011) 321–330abnormal. These abnormal granules were less dense than insulin
granules and were not surrounded by the characteristic halo (Fig. 5I,
arrowheads). Previous data, together with our data here (Figs. 4
and 5), suggest that neural crest-derived cells regulate beta cell
development in two independent manners. First, neural crest cells
regulate Nkx2.2 expression, proliferation of insulin-expressing cells
and insulin-positive area (Fig. 4) (Nekrep et al., 2008). Second, neural
crest cells positively regulate expression of MafA and Pdx1, and thus,
beta cell maturation (Fig. 5).
Neural crest-derived cells directly contact insulin- and
glucagon-expressing cells
To determine whether neural crest derivatives signal to insulin-
expressing cells through juxtracrine or paracrine signaling, high
magniﬁcation images of insulin-expressing cell clusters from control
animals were analyzed. By 15.5 dpc, approximately 55% of insulin-
expressing clusters were in direct contact with TUJ1-positive neurons
(Fig. 6A, D). This increased to approximately 84% of insulin-expressing
clusters in contactwith TUJ1-positive neurons by 17.5 dpc (Fig. 6 B, D),
and continued until postnatal day 1 when nearly every insulin-
expressing cluster (98.9%) was contacted by TUJ1-positive neurons
(Fig. 6C,D). In addition, by 17.5 dpc we detected TUJ1-positive
projections between endocrine cells (Fig. 6B, inset) demonstrating
that by late embryogenesis, neural crest derivatives enter endocrine
cell clusters. Together, these data suggest a model where neural crest-
derived cells signal to the pancreas through juxtracrine signaling and
this mechanism of regulation of beta cell development begins prior to
15.5 dpc.
Conclusion
To understand the importance of the neural crest on development
of the pancreatic primordium,we ﬁrst sought to precisely characterize
the timing of neural crest arrival at the developing pancreas and
determined that neural crest enters the pancreatic mesenchyme
between the 26 and 27 somite stages (approximately 10.0 dpc, Model
in Fig. 7A). As the pancreatic epithelium branches and invades the
surrounding mesenchyme, neural crest cells intermingle with acinar
and pancreatic endocrine cells (Fig. 7A). By 15.5 dpc, the majority of
insulin-expressing cell clusters were directly contacted by neural
crest derivatives, suggesting that these cells may signal through direct
cell–cell contact. This process is complete by postnatal day 1 when the
overwhelming majority of insulin-expressing cell clusters were
contacted by neural crest derivatives. Our data, for the ﬁrst time,
precisely deﬁne the stage at which this critical ectoderm–endodermFig. 6. Neurons directly contact insulin-expressing cells. (A–C) High-resolution (100X) co
positive neurons (green) directly contact insulin-expressing beta cells (red) at 15.5 dpc (
expressing beta and alpha cells at 17.5 dpc (B), and postnatal day 1 (C). The inset in B is an e
insulin (red)-expressing cell at 17.5 dpc. Arrows indicate TUJ1-positive cells in direct cont
contact with glucagon (blue)-expressing cells. (D) Quantiﬁcation of the number of insulin-p
bars indicate SEM. N=2–3 embryos/animals with at least 10 insulin-positive clusters per sinteraction is initiated, and conﬁrms that neural crest is the sole
source of pancreatic neurons and glia.
Earlier work demonstrated that loss of neural crest increased
proliferation and, therefore increased the overall number of insulin-
expressing cells present in the embryonic pancreas (Nekrep et al.,
2008). We show here, that in the absence of Foxd3, and therefore the
neural crest, the insulin-expressing area increased but, in addition,
expression of beta cell maturation markers decreased, suggesting that
neural crest promotes differentiation of insulin-expressing cells to
mature beta cells. In the absence of neural crest, increased
proliferation of insulin-expressing cells is associated with decreased
or delayed beta cell maturation, suggesting that the immature beta
cells are expanding (Fig. 7B). Our work demonstrates a novel manner
by which the ectodermally-derived neural crest inﬂuences develop-
ment of the endodermally-derived beta cell and shows for the ﬁrst
time that neural crest derivatives are critical regulators of beta cell
development and maturation. This in turn suggests that identiﬁcation
of neural crest-derived signals may be important for the optimization
of generation of glucose-responsive beta cells in vitro. Currently, in the
most successful methods of producing human embryonic stem cell
(hESC)-derived beta cells, the insulin-expressing cells stall at an
immature beta-cell stage (D'Amour et al., 2006). However, transplan-
tation of a heterogeneous population of cells consisting mostly of
pancreatic progenitor cells into adipose tissue or the kidney capsule of
a host mouse provides a permissive environment for beta cell
development and maturation, and transplanted cells become glucose
responsive and can rescue glucose stimulated insulin secretion in a
beta cell ablated mouse model (Kroon et al., 2008). To our knowledge,
no one has examined innervation in these models and it is possible
that contaminating ectodermal cells were transplanted and/or that
resident postnatal neural crest progenitor cells in the host may
function to facilitate beta cell maturation in situ. Co-culture of neural
crest stem cells and adult islets in vitro increases beta cell
proliferation and function (Olerud et al., 2009), therefore, identiﬁca-
tion of neural crest-speciﬁc factors that augment beta-cell maturation
has the potential to improve these directed differentiation schemes.
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